Abingdon Health relies on Ginolis LFDA-6 to manufacture lateral flow tests

A suite of Ginolis LFDA assembly solutions helps Abingdon Health to produce tens of millions of rapid tests per year. The combination of Abingdon Health’s long-established lateral flow manufacturing expertise and Ginolis LFDA technology enables the company to achieve the company’s mission: To improve life by making rapid results accessible to all.

Global rapid test availability in higher volumes and lower prices 

Abingdon Health is a long-established lateral flow test manufacturer, who passionately pursues its mission to improve life by making rapid results accessible to all. With huge, 21st century technological advances in the speeds of online data transfer, modern society has become more and more expectant of immediate access to information. 

The company believes that fast access to information should not be limited to the internet. They aim to facilitate much faster access to results in health testing than traditional lab-based testing can deliver. Lateral flow tests are an accessible and very convenient way for Abingdon Health to enable these rapid results. 

To put it simply, more convenient access to health testing and faster results will ultimately help save more lives. Investing in knowledgeable employees and state-of-the-art equipment enables the company to maintain the quality production of lateral flow devices and manufacture in much higher volumes and lower prices, ensuring their tests are globally available to everyone.

Reliable, long-term partnership with Ginolis

“Ginolis are a well-established, international supplier of lateral flow tests assembly machinery, who, like us, have seen large increases in demand for their goods over the last 18 months,” says Oliver Gardner, the Chief Operating Officer of Abingdon Health. “Before the COVID-19 outbreak, Abingdon Health was already a Ginolis customer, and indeed we have owned the second LFDA machine that came off the Ginolis production line for a number of years. Therefore, this technology is proven to us, so Ginolis was the obvious choice for us to partner with, as we looked to increase our automated assemble capacity. Abingdon Health and Ginolis have a great relationship, and this has been strengthened during the COVID-19 pandemic.”

Reproducible quality is vital for manufacturing accurate lateral flow tests. According to Abingdon Health, Ginolis certainly facilitates this to a large extent. The Ginolis LFDA system is flexible enough to work with the lateral flow test specifications of the company’s clients, enabling them to load multiple different tests onto the machines. This allows the company to offer flexible lateral flow manufacturing solutions in vastly increased volumes and at lower prices as part of their automated services.

Abingdon Health now has a suite of LFDA systems across our facilities, which helps the company produce tens of millions of rapid tests per year. 

“The LFDA technology alongside our long-established lateral flow manufacturing know-how is a great combination and enables us to work with many new customers on a whole array of different lateral flow tests,” says Oliver Gardner. “This ultimately helps us achieve our mission: To improve life by making rapid results accessible to all.”

About Abingdon Health

Abingdon Health is a leading developer and contract manufacturer of high-quality lateral flow rapid tests. Abingdon Health works with a global customer base and takes projects from concept to routine manufacture or scales up newly developed and/or existing tests into large-scale manufacturing. 

The company has also developed and marketed its own labelled tests such as AbC-19TM, a Covid-19 Antibody lateral flow test. Abingdon Health supports the increasing need for rapid results across many industries and produces lateral flow tests in areas such as infectious disease, clinical testing, animal health and environmental testing. 

Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. To learn more, visit www.abingdonhealth.com.

Lateral flow test manufacturing with Ginolis LFDA-6

Ginolis LFDA-6 is a standard system for a fully automated assembly of lateral flow tests. The unique desktop approach takes a smaller footprint than traditional automation, saving valuable space in the production facilities. In addition, Ginolis LFDA modular automation solutions are easy to reconfigure to meet changing needs, whether there is a need to redesign the process or replace the entire product. The scalability of the Ginolis LFDA solutions enables increased production capacity by multiplying production processes.

Introducing Kaiku: New Data Insights in Manufacturing

Ginolis is proud to announce the launch of Kaiku, a groundbreaking software designed to provide unparalleled insights into manufacturing processes. Kaiku represents a significant leap forward in data analytics and process optimization.

A Journey of Innovation and Transformation

A Journey of Innovation and Transformation

Ginolis has undergone a significant internal transformation, prompting a strategic reassessment of our brand identity to align with our current operation and customer segments. This evolution has strengthened our position in the market and enabled us to meet our customers’ evolving needs.   

Introducing CEO Ginolis

Appointment news

Kauko Väinämö has been appointed as CEO of Ginolis Oy from September 1, 2022. Kauko has more than 30 years of solid knowledge in strategic leadership, having managed factories and R&D organizations in various technology sectors.

Send us your application!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

We can answer all your questions!